Therapeutic areas. Targeted care across key pathways

At the intersection of innovation and care, our integrated therapeutic approach supports patients across three vital domains: neurology, ophthalmology, and musculoskeletal health.

From restoring movement and managing chronic pain, to preserving vision and navigating complex neurological conditions, our mission is to empower lives through science-backed, human-centered solutions.

Therapeutic areas

Musculoskeletal

At the heart of our musculoskeletal expertise lies a singular mission: to restore mobility and quality of life. From the early management of tendinopathies to the relief of osteoarthritis pain, our solutions are built around the potential of hyaluronic acid – a naturally occurring molecule essential to joint and tissue health.¹

Explore

Ophthalmology

We are dedicated to improving ocular comfort and eye health. For over twenty five years, our work has focused on supporting patients with dry eye disease and assisting surgeons. Our formulations are mostly based on sodium hyaluronate technology, designed to protect the ocular surface, reduce discomfort, and enhance visual outcomes in both daily care and surgical settings.^2,3

Explore

Sports medicine

From overuse strains to acute injuries, our focus is on helping people return to motion. We research evidence-based solutions rooted in musculoskeletal science, such as hyaluronic acid, to support tissue repair and restore function for athletes and active individuals.⁴

Explore

Neurology

For over two decades, TRB has advanced research in neurological and neurodegenerative disorders such as Parkinson’s disease and stroke. Our long – standing work with GM1 ganglioside focuses on its neuroprotective and restorative properties,^5–7 driving continued innovation and collaboration in the field.

Explore

References

Papakonstantinou E, Roth M, Karakiulakis G. Hyaluronic acid: A key molecule in skin aging. Dermatoendocrinol. 2012;4(3):253–258.
Hynnekleiv L, Magno M, Vernhardsdottir RR, et al. Hyaluronic acid in the treatment of dry eye disease. Acta Ophthalmol. 2022;100(8):844-860.
Belda JI, Artola A, García-Manzanares MD, et al. Hyaluronic acid combined with mannitol to improve protection against free-radical endothelial damage: experimental model. J Cataract Refract Surg. 2005;31(6):1213–1218.
Oliva F, Marsilio E, Asparago G, et al. The impact of hyaluronic acid on tendon physiology and its clinical application in tendinopathies. Cells. 2021;10(11):3081.
Schneider JS, Gollomp SM, Sendek S, et al. A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson’s disease patients. J Neurol Sci. 2013;324(1-2):140–148.
Alpaugh M, Galleguillos D, Forero J, et al. Disease-modifying effects of ganglioside GM1 in Huntington’s disease models. EMBO Mol Med. 2017;9(11):1537–1557.